Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „rituximab“
Suchtreffer
Begriffe & Kennungen
Ituxredi · 4.8 · Patients received 2 x 1000 mg of rituximab separated by an interval of two weeks; in addition to methotrexate
Eintrag öffnenItuxredi · 4.8 · Table 5 Adverse reactions occurring at 6-months in ≥ 5% of adult patients receiving rituximab in GPA/MPA Study
Eintrag öffnenItuxredi · 4.8 · Table 7 Adverse reactions in rituximab-treated pemphigus vulgaris patients in PV Study 1 (up to Month 24) and
Eintrag öffnenItuxredi · 4.8 · The frequencies of adverse reactions reported with rituximab alone or in combination with chemotherapy are sum
Eintrag öffnenItuxredi · 4.8 · The most frequently observed adverse reactions in patients receiving rituximab were IRRs which occurred in the
Eintrag öffnenItuxredi · 4.8 · The overall safety profile of rituximab in adult and paediatric GPA/MPA patients is based on data from patient
Eintrag öffnenItuxredi · 4.8 · The overall safety profile of rituximab in non-Hodgkin’s lymphoma and CLL is based on data from patients from
Eintrag öffnenItuxredi · 4.8 · The overall safety profile of rituximab in pemphigus vulgaris is based on data from patients from 2 clinical t
Eintrag öffnenItuxredi · 4.8 · The overall safety profile of rituximab in rheumatoid arthritis is based on data from patients from clinical t
Eintrag öffnenItuxredi · 4.8 · The overall safety profile was consistent with the well-established safety profile for rituximab in approved a
Eintrag öffnenItuxredi · 4.8 · The safety profile of rituximab in PV was consistent with the established safety profile in other approved aut
Eintrag öffnenItuxredi · 4.8 · The safety profile of rituximab in paediatric GPA or MPA patients was consistent in type, nature and severity
Eintrag öffnenItuxredi · 4.8 · The safety profile of rituximab in paediatric patients (aged 6 months to less than 18 years old) with previous
Eintrag öffnenItuxredi · 4.8 · The safety profile of rituximab in patients with moderate to severe rheumatoid arthritis (RA) is summarised in
Eintrag öffnenLenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka) · 4.8 · 32 or 4 thrombocytopenia (1.4% in lenalidomide/rituximab treated patients compared to 0% in placebo/rituximab
Eintrag öffnenLenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka) · 4.8 · 33 arm versus 1/148 (0.7%) patients in the placebo/rituximab arm. Most TFRs (18 out of 19) reported in the len
Eintrag öffnenLenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka) · 4.8 · Follicular lymphoma The overall safety profile of lenalidomide in combination with rituximab in patients with
Eintrag öffnenLenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka) · 4.8 · Follicular lymphoma patients The combination of lenalidomide with rituximab in follicular lymphoma is associat
Eintrag öffnenLenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka) · 4.8 · In the NHL-007 study the adverse reactions observed more frequently in the lenalidomide/rituximab arm compared
Eintrag öffnenLenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka) · 4.8 · Lenalidomide in combination with rituximab is also associated with a higher incidence of Grade 3
Eintrag öffnen